Abstract

This study was conducted to explore the potential genes and proteins associated with esophagus benign hyperplasia induced by esophageal stents. Five patients with esophageal cancer subjected to esophageal stent placement were enrolled in this study. Long non-coding RNA (lncRNA) sequencing and tandem mass tag quantitative proteomics analysis were performed by using the collected hyperplastic samples and adjacent non-hyperplastic tissues. Differentially expressed (DE) RNAs and proteins were analyzed, followed by functional enrichment analysis, protein-protein interaction (PPI) network analysis, and competitive endogenous RNA (ceRNA) network construction. Venn analysis was performed to extract the overlaps between DE mRNAs and DE proteins and the expression correlations between DE mRNA and proteins were analyzed. Results showed that total 642 DE RNAs (457 mRNA and 185 lncRNAs) and 256 DE proteins were detected. DE mRNAs (such as MAOB, SDR16C5, and FOSL1) were enriched in oxidation-reduction process-associated functions. PPI network was comprised of 175 nodes and 425 edges. VEGFA was a significant node with the highest degree. LncRNA-mRNA network with three subnetworks (C1, C2, C3) was constructed for lncRNAs with more than 15 gene targets. RP11-58O9.2 was a significant lncRNA with the most target genes and RP11-667F14.1 regulated more than 20 targets. FOSL1 was a common target of the two lncRNAs. Function analysis showed that DE lncRNAs were involved in the HTLV-I infection (RP11-58O9.2 and RP11-667F14.1) and IL-17 signaling pathways (RP11-5O24.1 and RP11-58O9.2). Total 11 DE mRNAs were overlapped with DE proteins, among which MAOB and SDR16C5 showed positive correlations between mRNA and protein expression. Function analysis showed that MAOB was enriched in oxidation-reduction process and its protein was closely related with response to lipopolysaccharide. VEGFA, FOSL1, MAOB, SDR16C5, RP11-58O9.2, RP11-667F14.1, and RP11-288A5.2 may be served as genetic targets for preventing stent restenosis in esophageal cancer.

Highlights

  • Esophageal cancer is one of the most common human cancers globally and a leading cause of cancer-related deaths, with an estimated 400,000 deaths in 2012 (Ferlay et al, 2013)

  • Tissue benign hyperplasia-induced stent restenosis is a common complication influencing the longterm effect of stent placement, no methods have been developed to overcome this problem

  • 36 33 33 32 31 27 27 26 26 26 we combined high-throughput sequencing and proteomics technologies to explore the genetic and protein markers associated with benign hyperplasia caused by restenosis after esophageal stent placement

Read more

Summary

INTRODUCTION

Esophageal cancer is one of the most common human cancers globally and a leading cause of cancer-related deaths, with an estimated 400,000 deaths in 2012 (Ferlay et al, 2013). Dysphagia is the most common symptom of obstructive esophageal cancer (Mariette et al, 2007), which may lead to malnutrition and eventually result in a poor treatment response and poor prognosis (Mariette et al, 2012). Benign tissue hyperplasia-induced stent restenosis is the most intractable complication with an incidence of up to 46.1% (Hindy et al, 2012). Experiments using animal models indicated that 125I seeds cannot prevent benign tissue hyperplasia-induced stent restenosis (Guo et al, 2007). We enrolled five patients with esophageal cancer who had undergone esophagus 125I stent placement and explored the potential genes and proteins associated with esophagus benign hyperplasia induced by esophageal stents. Transcriptome and proteomics data were analyzed by bioinformatics methods and validated by reverse transcription (RT)-PCR and western blot analyses

RESULTS
DISCUSSION
MATERIALS AND METHODS
DATA AVAILABILITY STATEMENT
ETHICS STATEMENT

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.